Volume 5.17 | May 16

Prostate Cell News 5.17 May 16, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
SKA1 Overexpression Promotes Centriole Over-Duplication, Centrosome Amplification and Prostate Tumorigenesis
Researchers report that spindle and kinetochore associated protein 1 (Ska1) overexpression promotes prostate tumorigenesis. Immunohistochemistry and quantitative RT-PCR analysis revealed that Ska1 was overexpressed in human prostatic intraepithelial neoplasia, the most likely prostate cancer precursors, and adenocarcinomas. [J Pathol] Abstract
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™
PUBLICATIONS (Ranked by impact factor of the journal)

Regulation of SRC Kinases by MicroRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer
Scientists examined the functional significance of miR-3607 in prostate cancer cell lines and found that miR-3607 overexpression led to significantly decreased proliferation, apoptosis induction and decreased invasiveness. [Mol Cancer Ther] Abstract

Androgen Receptor as a Regulator of ZEB2 Expression and Its Implications in Epithelial-to-Mesenchymal Transition in Prostate Cancer
Zinc finger E-box-binding protein 2 (ZEB2) expression was found to be significantly upregulated after androgen stimulation and downregulated following androgen receptor silencing in LNCaP cells, an androgen-dependent prostate cancer cell line. [Endocr Relat Cancer] Abstract

VDR Activity Is Differentially Affected by Hic-5 in Prostate Cancer and Stromal Cells
Transforming growth factor-beta, which is associated with the development of tumorigenic “reactive stroma” in prostate cancer, induced VDR expression in the human WPMY-1 prostate stromal cell line. [Mol Cancer Res] Abstract

Overexpression of HepaCAM Inhibits Cell Viability and Motility through Suppressing Nucleus Translocation of Androgen Receptor and ERK Signaling in Prostate Cancer
HepaCAM expression was significantly down-regulated in prostate cancer tissues and undetected in prostate cancer cells. However, low HepaCAM expression was not statistically associated with clinicopathological characteristics of prostate cancer. [Prostate] Abstract

Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging
A muJ591:Molday ION Rhodamine-B Carboxyl complex reduced cell adhesion and cell proliferation on LNCaP cells and caused apoptosis as tested by Annexin V assay, suggesting anti-tumorigenic characteristics. [PLoS One] Full Article

Tumor-Suppressive MicroRNA-218 Inhibits Cancer Cell Migration and Invasion via Targeting of LASP1 in Prostate Cancer
Researchers investigated the functional significance of microRNA (miR)-218 in prostate cancer (PCa) and to identify novel miR-218-regulated cancer pathways and target genes involved in PCa oncogenesis and metastasis. [Cancer Sci] Abstract

Tumor-Suppressive MicroRNA-29s Inhibit Cancer Cell Migration and Invasion via Targeting LAMC1 in Prostate Cancer
Scientists investigated the functional significance of microRNA (miR)-29 in cancer cells and to identify novel miR-29s-mediated cancer pathways and target genes involved in prostate cancer oncogenesis and metastasis. [Int J Oncol] Abstract


Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance
Researchers hypothesized that compared to the estimated dietary omega-3 (ω-3) fatty acids intake and the ω-3 fatty acids level measured in red blood cells, the prostate tissue ω-3 fatty acids content is more strongly related to prostate cancer (PCa) progression. They present the initial observations from baseline data of a Phase II clinical trial conducted in a cohort of 48 untreated men affected with low-risk PCa, managed under active surveillance. [Cancer Prev Res] Abstract

Serum Fucosylated Haptoglobin as a Novel Prognostic Biomarker Predicting High-Gleason Prostate Cancer
Scientists measured the preoperative serum fucosylated haptoglobin (Fuc-Hpt) levels in 98 patients who underwent radical prostatectomy using an established lectin-antibody ELISA. Serum Fuc-Hpt levels were significantly associated with Gleason score, but not prostate-specific antigen levels. [Prostate] Abstract

Free Cell Stem Cell Poster: Directed Differentiation of ESCs/iPSCs
Circulating Tumor Cells – Monitoring Treatment Response in Prostate Cancer
The authors describe the challenges associated with monitoring treatment response in metastatic castration-resistant prostate cancer, and the advancements in circulating tumor cells-analysis technologies applied to such assessments and, ultimately, guiding prostate cancer treatment. [Nat Rev Clin Oncol] Abstract

In Vitro Modeling of the Prostate Cancer Microenvironment
This article presents the current state of in vitro models for prostate cancer, with particular emphasis on 3D systems and the challenges that remain before their potential to advance our understanding of prostate disease and aid in the development and testing of new therapeutic agents can be realized. [Adv Drug Deliv Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Orteronel plus Prednisone Improved Progression Free Survival in Men with Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase III Study
Takeda Pharmaceutical Company Limited announced data from ELM-PC4, a pivotal, international, double blind, randomized Phase III trial showing that the investigational drug orteronel plus prednisone reduced the risk of radiographic progression free survival, one of the study’s two primary endpoints, by 30% compared to placebo plus prednisone in men with chemotherapy-naïve metastatic castration resistant prostate cancer. [Press release from Takeda Pharmaceutical Company Limited discussing research to be presented at annual meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
TOLMAR Pharmaceuticals Established to Market ELIGARD for Advanced Prostate Cancer in the U.S. and Puerto Rico
TOLMAR Pharmaceuticals, Inc. announced that the company holds exclusive distribution rights to ELIGARD® in the U.S. and Puerto Rico. ELIGARD is a prescription medication for the palliative treatment of advanced prostate cancer. [TOLMAR Pharmaceuticals, Inc.] Press Release

NICE Issues Preliminary Recommendations on Earlier Treatment with Abiraterone for Prostate Cancer
In draft guidance published NICE has not recommended abiraterone for prostate cancer which has spread in people whose first treatment has failed, have no or mild symptoms and for whom chemotherapy is not yet clinically indicated. [National Institute for Health and Care Excellence (NICE)] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Case Western Reserve University (CWRU): National Center for Regenerative Medicine Cancer Stem Cell Conference
August 17-20, 2014
Cleveland, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

PhD Student Position – Development of Phellinus linteus as an Anti-Prostate Cancer Drug (Sahlgrenska Academy)

Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

PhD Position – 3D Cell Culture & Microfluidics: New Insights in Prostate Cancer (CEA French Atomic and Alternative Energies Commission)

Postdoctoral Position – Nuclear Import Mechanisms for the Androgen Receptor and Its Variants (Cornell University)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us